Hong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development

Stock News

10/08

VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1188508612"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188508612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188508612?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188508612","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development","media":"Stock News","content":"<p>VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | VIVA BIOTECH (01873) Surges Over 10% in Afternoon Trading as AI Pharmaceutical Business Model Shows Validation, Company Takes Forward-Looking Approach in AI Drug Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-08 14:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1188508612","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188508612","pubTimestamp":1759903578,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物","BK1141":"生命科学工具和服务","HSCEI":"国企指数","BK1576":"医药外包概念","01477":"欧康维视生物-B","BK4614":"Manus概念股","07226":"南方两倍做多恒科","BK1191":"制药","YANG":"三倍做空富时中国ETF-Direxion","BK1574":"生物医药B类股"},"translate_title":"港股快讯|维亚生物(01873)午后大涨超10%AI制药商业模式显示验证，公司在AI药物开发方面采取前瞻性做法","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01873":1,"07226":1,"HSCEI":1,"YANG":1},"content_text":"VIVA BIOTECH (01873) surged over 10% in afternoon trading. As of press time, the stock rose 10.45% to HK$3.17, with trading volume reaching HK$32.0142 million. On the news front, multiple new AI pharmaceutical contracts have been added globally recently. Guoyuan International noted that VIVA BIOTECH has been positioning itself in AI pharmaceuticals since five years ago, with AI-related orders currently accounting for 12% of newly signed contracts and showing a growing trend. Huaxin Securities stated that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, which is an important application scenario for AI that can enhance drug development efficiency and success rates. Therefore, the company launched an AI-integrated drug development platform called AIDD for its clients. As of the first half of 2025, AIDD has cumulatively participated in the development of 175 projects, with AI-enabled CRO business accounting for 10% of total revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}